Xtant Medical Holdings, Inc. XTNT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -64.08%
- 1 year
- -69.54%
- Open
- 0.281
- Prev close
- 0.2904
- Mkt cap
- 39.31M
- Vol
- 44.52K
- Avg vol
- 1.69M
- EPS
- -0.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2802
- High
- 0.2964
- Forward P/E
- -13.43
- Beta
- 0.39
- Short ratio
- 6.92
- Inst. own
- 65.12%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.467
- 200-d avg
- 0.68755
- 1y target
- 2.25
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
-
2 months ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Xtant Medical Holdings with Buy Rating, Announces Price Target of $1
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Xtant Medical Holdings (AMEX:XTNT) with a Buy rating and announces Price Target of $1.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
-
2 months ago benzinga.com
Xtant Medical Enters Exclusive Partnership With Henry Schein's Biohorizons To Distribute The Company's Allogeneic Growth Factor Technology Under The Prolifica Private Brand
The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and…
2 months ago prnewswire.com
Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market
Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
2 months ago seekingalpha.com
Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript
Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
-
2 months ago benzinga.com
Xtant Medical Hldgs Q2 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $23.031M Miss $24.875M Estimate
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 250 percent decrease over earnings of…
-
2 months ago benzinga.com
Xtant Medical Hldgs Lowers FY2026 Sales Guidance from $101.000M-$105.000M to $99.000M-$103.000M vs $102.058M Est
Xtant Medical Hldgs (AMEX:XTNT) lowers FY2026 sales outlook from $101.000 million-$105.000 million to $99.000 million-$103.000 million vs $102.058 million estimate.
2 months ago prnewswire.com
Xtant Medical Reports Second Quarter 2026 Financial Results
Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and…
2 months ago prnewswire.com
Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026
BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic…
2 months ago prnewswire.com
Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference
BELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic…
5 months ago marketbeat.com
Xtant Medical Q1 Earnings Call Highlights
Xtant Medical NYSEAMERICAN: XTNT raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter…
5 months ago seekingalpha.com
Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript
Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
BTIG Reiterates Buy on Xtant Medical Holdings, Maintains $1 Price Target
BTIG analyst Ryan Zimmerman reiterates Xtant Medical Holdings (AMEX:XTNT) with a Buy and maintains $1 price target.
-
5 months ago benzinga.com
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Xtant Medical Raises FY2026 Sales Guidance from $95.000M-$99.000M to $101.000M-$105.000M vs $96.725M Est
2026 Financial GuidanceThe Company is today increasing its full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect the…
-
5 months ago benzinga.com
Xtant Medical Hldgs Q1 EPS $(0.02), Inline, Sales $20.884M Beat $20.164M Estimate
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. The company reported quarterly sales of $20.884 million which beat the analyst…
5 months ago prnewswire.com
Xtant Medical Reports First Quarter 2026 Financial Results
Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST®…
5 months ago prnewswire.com
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,…
5 months ago prnewswire.com
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
6 months ago benzinga.com
Xtant Medical Holdings Acquires Exclusive U.S. Distribution Rights To Dilon Technologies' HEMOBLAST Bellows
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical…
6 months ago prnewswire.com
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE,…
6 months ago prnewswire.com
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced…
-
7 months ago benzinga.com
BTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $1.5 to $1.
7 months ago seekingalpha.com
Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
-
7 months ago benzinga.com
Xtant Medical Hldgs Sees FY2026 Sales $95.000M-$99.000M vs $110.100M Est
Xtant Medical Hldgs (AMEX:XTNT) sees FY2026 sales of $95.000 million-$99.000 million vs $110.100 million analyst estimate.
-
7 months ago benzinga.com
Earnings Scheduled For March 31, 2026
Earnings Scheduled For March 31, 2026
-
7 months ago benzinga.com
Xtant Medical Hldgs Q4 Sales $32.357M Beat $30.750M Estimate
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly sales of $32.357 million which beat the analyst consensus estimate of $30.750 million by 5.23 percent. This is a 2.68 percent increase over sales of…
7 months ago prnewswire.com
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December…
7 months ago prnewswire.com
Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
8 months ago benzinga.com
Xtant Medical Receives $10.7M Related To Companion Spine's Purchase Of Xtant's Coflex Assets And Paradigm OUS Businesses, Bringing Total Price For Two Divestitures To $21.4M
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustmentsBELGRADE, Mont., March 2, 2026 /PRNewswire/ --…
8 months ago prnewswire.com
Xtant Medical Finalizes Companion Spine Transactions
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ --…
8 months ago prnewswire.com
Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal,…
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
10 months ago defenseworld.net
AWM Investment Company Inc. Takes $4.88 Million Position in Xtant Medical Holdings, Inc. $XTNT
AWM Investment Company Inc. purchased a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the undefined quarter, according to its most recent 13F filing with the Securities…
10 months ago prnewswire.com
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE,…
11 months ago prnewswire.com
Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
BELGRADE, Mont. , Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic…
-
11 months ago benzinga.com
BTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1.5
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $2 to $1.5.
-
11 months ago benzinga.com
Xtant Medical Hldgs Affirms FY2025 Sales Guidance of $131.000M-$135.000M vs $129.950M Est
Xtant Medical Hldgs (AMEX:XTNT) affirms FY2025 sales outlook from $131.000 million-$135.000 million to $131.000 million-$135.000 million vs $129.950 million estimate.
-
11 months ago benzinga.com
Xtant Medical Hldgs Q3 EPS $0.01 Beats $(0.01) Estimate, Sales $33.300M Beat $32.700M Estimate
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 125 percent increase over losses of…
-
11 months ago benzinga.com
Earnings Preview For Xtant Medical Hldgs
Earnings Preview For Xtant Medical Hldgs
-
1 year ago benzinga.com
Xtant Medical Hldgs Raises FY2025 Sales Guidance from $127.000M-$131.000M to $131.000M-$135.000M vs $129.550M Est
Xtant Medical Hldgs (AMEX:XTNT) raises FY2025 sales outlook from $127.000 million-$131.000 million to $131.000 million-$135.000 million vs $129.550 million estimate.